MT1L and neoplasm: The function of metallothioneins in drug resistance has been well documented (Cherian et al, 2003; Theocharis et al, 2004; Surowiak et al, 2007), and an earlier transcriptomic study of OS reported up-regulation of MTIG and MT1L in poorly responsive tumours (Mintz et al, 2005).